Lucid Diagnostics
Lucid Diagnostics is a medical diagnostics company dedicated to revolutionizing cancer prevention through innovative, non-invasive technologies. Their mission is to enable early detection and treatment of esophageal precancer, thereby preventing its progression to lethal cancer. They develop and commercialize advanced molecular diagnostic tests, such as the EsoGuard DNA test, which detects esophageal precancer and cancer in a simple office-based visit without the need for endoscopy. The company is committed to improving patient outcomes through early diagnosis, research, and collaboration with clinicians and healthcare providers.
Industries
Nr. of Employees
medium (51-250)
Patents
Products
Non‑endoscopic esophageal cell collection device (swallowable capsule with inflatable balloon)
A swallowable capsule that deploys a textured inflatable balloon to collect circumferential surface cells from the distal esophagus and then inverts to protect the sample during retrieval, enabling unsedated office‑based sampling.
Targeted DNA methylation diagnostic test for esophageal precancer (central lab assay)
A laboratory diagnostic test that evaluates methylation at multiple targeted genomic locations using bisulfite conversion and targeted NGS to identify epigenetic signatures associated with Barrett's esophagus and esophageal adenocarcinoma; intended as an office‑based screening or triage test to endoscopy.
Non‑endoscopic esophageal cell collection device (swallowable capsule with inflatable balloon)
A swallowable capsule that deploys a textured inflatable balloon to collect circumferential surface cells from the distal esophagus and then inverts to protect the sample during retrieval, enabling unsedated office‑based sampling.
Targeted DNA methylation diagnostic test for esophageal precancer (central lab assay)
A laboratory diagnostic test that evaluates methylation at multiple targeted genomic locations using bisulfite conversion and targeted NGS to identify epigenetic signatures associated with Barrett's esophagus and esophageal adenocarcinoma; intended as an office‑based screening or triage test to endoscopy.
Services
Laboratory diagnostic service that performs targeted DNA methylation analysis on collected esophageal cell samples and returns a positive/negative report indicating detection of epigenetic changes consistent with precancer or cancer.
Supply of a swallowable capsule device and clinician resources to perform office‑based distal esophageal cell collection without endoscopy, including training and materials for sample protection and transport.
Coordination and execution of high‑volume community and occupational screening events using mobile testing units and staffed collection teams for targeted populations.
Direct billing to medical insurance carriers, management of claims, and administration of a financial assistance program and payment plans to reduce out‑of‑pocket cost for patients.
Laboratory diagnostic service that performs targeted DNA methylation analysis on collected esophageal cell samples and returns a positive/negative report indicating detection of epigenetic changes consistent with precancer or cancer.
Supply of a swallowable capsule device and clinician resources to perform office‑based distal esophageal cell collection without endoscopy, including training and materials for sample protection and transport.
Coordination and execution of high‑volume community and occupational screening events using mobile testing units and staffed collection teams for targeted populations.
Direct billing to medical insurance carriers, management of claims, and administration of a financial assistance program and payment plans to reduce out‑of‑pocket cost for patients.
Expertise Areas
- Non‑endoscopic esophageal screening
- Molecular diagnostics (DNA methylation assays)
- Clinical study design and registry generation
- Analytical validation of diagnostic assays
Key Technologies
- Targeted next‑generation sequencing (targeted NGS)
- DNA methylation analysis (bisulfite conversion)
- Swallowable balloon‑based esophageal cell collection
- Copy number alteration (CNA) analysis and somatic mutation detection (e.g., TP53)
News & Updates
Anderson County, SC firefighters were offered esophageal pre-cancer screenings using the EsoGuard DNA test, at an event organized by Honea Path Fire Chief and physician Jimmy Smith. The screening involves swallowing a balloon-equipped capsule to collect esophageal cells, a process taking about five minutes. Firefighters have a 62% higher risk of esophageal cancer due to toxic materials in modern building materials. Anderson City Fire Chief Charlie King emphasized the importance of early detection. Smith noted that early diagnosis and treatment can prevent the progression to fatal cancer. The screenings are also recommended for individuals with risk factors, such as family history.
Many people experience occasional acid reflux. But if you have it all the time, it could lead to a very serious condition and in some cases, cancer. Now, there's a new screening test - the first and only of its kind - to detect precancerous issues. 'I started with heartburn,' said 68-year old Ignacio Perez. Long Beach gastroenterologist Dr. Seper Dezfoli explains that Barrett's esophagus, a condition where esophageal cells are replaced by stomach cells, can lead to cancer. See the news story: <https://abc7.com/post/esoguard-test-helps-early-detection-of-esophageal-cancer/>
The EsoCheck Esophageal Cell Collection Device received FDA 510(k) clearance, enabling non-invasive collection of esophageal cells for analysis.
The U.S. FDA granted Breakthrough Device Designation to the EsoGuard Esophageal DNA Test, recognizing its potential to address unmet medical needs in early detection of esophageal precancer.
Lucid Diagnostics launched the EsoGuard DNA test as a laboratory-developed test, making it available for clinical use.
Anderson County, SC firefighters were offered esophageal pre-cancer screenings using the EsoGuard DNA test, at an event organized by Honea Path Fire Chief and physician Jimmy Smith. The screening involves swallowing a balloon-equipped capsule to collect esophageal cells, a process taking about five minutes. Firefighters have a 62% higher risk of esophageal cancer due to toxic materials in modern building materials. Anderson City Fire Chief Charlie King emphasized the importance of early detection. Smith noted that early diagnosis and treatment can prevent the progression to fatal cancer. The screenings are also recommended for individuals with risk factors, such as family history.
Many people experience occasional acid reflux. But if you have it all the time, it could lead to a very serious condition and in some cases, cancer. Now, there's a new screening test - the first and only of its kind - to detect precancerous issues. 'I started with heartburn,' said 68-year old Ignacio Perez. Long Beach gastroenterologist Dr. Seper Dezfoli explains that Barrett's esophagus, a condition where esophageal cells are replaced by stomach cells, can lead to cancer. See the news story: <https://abc7.com/post/esoguard-test-helps-early-detection-of-esophageal-cancer/>
The EsoCheck Esophageal Cell Collection Device received FDA 510(k) clearance, enabling non-invasive collection of esophageal cells for analysis.
The U.S. FDA granted Breakthrough Device Designation to the EsoGuard Esophageal DNA Test, recognizing its potential to address unmet medical needs in early detection of esophageal precancer.
Lucid Diagnostics launched the EsoGuard DNA test as a laboratory-developed test, making it available for clinical use.